What is the Sweet Spot for Platelet Reactivity in Japanese Patients?
作者信息
Nakamura Masato
机构信息
Division of Cardiovascular Medicine, Toho University Ohashi Medical Center.
出版信息
J Atheroscler Thromb. 2020 Jan 1;27(1):1-3. doi: 10.5551/jat.ED118. Epub 2019 Aug 29.
Abstract
摘要
相似文献
1
What is the Sweet Spot for Platelet Reactivity in Japanese Patients?日本患者血小板反应性的最佳范围是什么？
J Atheroscler Thromb. 2020 Jan 1;27(1):1-3. doi: 10.5551/jat.ED118. Epub 2019 Aug 29.
2
Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China.在中国实际临床环境中，CYP2C19 变异等位基因对氯吡格雷抵抗血小板反应和临床结局的影响。
Pharmacogenet Genomics. 2012 Dec;22(12):887-90. doi: 10.1097/FPC.0b013e328359253a.
3
Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.除了 CYP2C19*2，CYP2C9*3 变异等位基因与接受择期冠状动脉支架植入术的双联抗血小板治疗患者的氯吡格雷血小板反应性升高相关。
Pharmacogenet Genomics. 2010 Jan;20(1):18-25. doi: 10.1097/FPC.0b013e328333dafe.
4
The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.中国患者中氯吡格雷治疗时的血小板反应性、基因型与经皮冠状动脉介入治疗术后结局的关系。
Scand J Clin Lab Invest. 2015 May;75(3):223-9. doi: 10.3109/00365513.2014.993696. Epub 2015 Jan 16.
5
Clopidogrel response variability: impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting.氯吡格雷反应变异性：基因多态性和血小板生物标志物对预测支架置入术后不良结局的影响
Am J Ther. 2015 May-Jun;22(3):222-30. doi: 10.1097/MJT.0000000000000125.
6
Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.CYP2C19基因多态性对接受氯吡格雷治疗的缺血性中风患者血小板反应性及临床结局的影响。
Eur J Pharmacol. 2015 Jan 15;747:29-35. doi: 10.1016/j.ejphar.2014.11.037. Epub 2014 Dec 6.
7
α2A-Adrenergic receptor polymorphism potentiates platelet reactivity in patients with stable coronary artery disease carrying the cytochrome P450 2C19*2 genetic variant.α2A-肾上腺素能受体多态性增强携带细胞色素 P450 2C19*2 遗传变异的稳定性冠心病患者的血小板反应性。
Arterioscler Thromb Vasc Biol. 2014 Jun;34(6):1314-9. doi: 10.1161/ATVBAHA.114.303275. Epub 2014 Apr 10.
8
Determinants of high on-treatment platelet reactivity and agreement between VerifyNow and Multiplate assays.治疗期间血小板高反应性的决定因素以及VerifyNow检测法与Multiplate检测法之间的一致性
Scand J Clin Lab Invest. 2017 May;77(3):190-198. doi: 10.1080/00365513.2017.1286686. Epub 2017 Feb 24.
9
The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy.临床参数以及CYP2C19 G681和CYP4F2 G1347A基因多态性在双联抗血小板治疗期间对血小板反应性的作用。
Blood Coagul Fibrinolysis. 2014 Jun;25(4):369-74. doi: 10.1097/MBC.0000000000000053.
10
Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.经皮冠状动脉介入治疗后联合使用氯吡格雷和质子泵抑制剂后，通过[(13)C] -泮托拉唑呼气试验评估CYP2C19酶活性的变化及其与血小板反应性的相关性。
J Breath Res. 2016 Jan 27;10(1):017104. doi: 10.1088/1752-7155/10/1/017104.
引用本文的文献
1
Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel.临床和遗传因素对接受氯吡格雷和普拉格雷治疗的冠心病患者高血小板反应性的差异影响
J Atheroscler Thromb. 2022 Jul 1;29(7):1031-1039. doi: 10.5551/jat.63035. Epub 2021 Jul 8.
本文引用的文献
1
Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation.双联抗血小板治疗后血小板高反应性与日本经皮冠状动脉介入治疗患者缺血事件的关系。
J Atheroscler Thromb. 2020 Jan 1;27(1):13-24. doi: 10.5551/jat.48934. Epub 2019 May 14.
2
Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study.经皮冠状动脉介入治疗术后血小板反应性与缺血性卒中风险：ADAPT-DES 研究。
JACC Cardiovasc Interv. 2018 Jul 9;11(13):1277-1286. doi: 10.1016/j.jcin.2018.01.263. Epub 2018 Jun 13.
3
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.Bococizumab 在高危患者中的心血管疗效和安全性。
N Engl J Med. 2017 Apr 20;376(16):1527-1539. doi: 10.1056/NEJMoa1701488. Epub 2017 Mar 17.
4
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.依洛尤单抗与心血管疾病患者的临床结局。
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
5
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).外周动脉疾病患者冠状动脉植入药物洗脱支架后的血小板反应性及临床结局：来自ADAPT-DES研究（药物洗脱支架双重抗血小板治疗评估）的分析
Circ Cardiovasc Interv. 2017 Mar;10(3). doi: 10.1161/CIRCINTERVENTIONS.116.004904.
6
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.依折麦布联合他汀类药物治疗急性冠脉综合征。
N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.
7
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.药物洗脱支架冠状动脉植入后血小板反应性与临床结局（ADAPT-DES）：一项前瞻性多中心登记研究。
Lancet. 2013 Aug 17;382(9892):614-23. doi: 10.1016/S0140-6736(13)61170-8. Epub 2013 Jul 26.
8
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.替格瑞洛与氯吡格雷用于急性冠脉综合征患者的比较
N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.
9
Prasugrel versus clopidogrel in patients with acute coronary syndromes.普拉格雷与氯吡格雷用于急性冠状动脉综合征患者的比较。
N Engl J Med. 2007 Nov 15;357(20):2001-15. doi: 10.1056/NEJMoa0706482. Epub 2007 Nov 4.
10
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.急性冠状动脉综合征后使用他汀类药物强化降脂与中度降脂的比较。
N Engl J Med. 2004 Apr 8;350(15):1495-504. doi: 10.1056/NEJMoa040583. Epub 2004 Mar 8.
Zotero 插件